Calidi Biotherapeutics (NYSE: CLDI) surged 39.47% after hours Tuesday, following renewed investor interest in its innovative cancer treatment developments.
Calidi Biotherapeutics (NYSE: CLDI) surged 39.47% after hours Tuesday, following renewed investor interest in its innovative cancer treatment developments.